ArticleActa pharmacologica Sinica2022

Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Jing-Yue Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.